GlassScriptPhysician profile
Joon K Lee
NPI 1396164208
$1,368.83
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.09 · 2020: $57.56 · 2021: $170 · 2022: $215 · 2023: $191 · 2024: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $387.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $547.57 | 2021-2024 | Imfinzi |
| Sirtex Medical INC | $142.35 | 2024 | Sir-Spheres Microspheres |
| Eisai INC. | $54.12 | 2021-2023 | |
| Janssen Biotech, INC. | $46.76 | 2021-2023 | Darzalex |
| Amgen INC. | $45.94 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Siemens Medical Solutions USA, INC. | $38.81 | 2023 | Aria Radiation Therapy Management Software |
| Seagen INC. | $36.07 | 2022-2023 | Adcetris |
| Astellas Pharma US INC | $34.35 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $33.70 | 2022-2023 | Pyrukynd |
| E.R. Squibb & Sons, L.L.C. | $32.35 | 2019-2022 | |
| Genzyme Corporation | $32.05 | 2021-2023 | |
| Boston Scientific Corporation | $30.49 | 2024 | Spaceoar Vue System - 10ml |
| Daiichi Sankyo INC. | $29.63 | 2020-2023 | Injectafer |
| Incyte Corporation | $29.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $24.49 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $24.36 | 2024 | Optune |
| Pharmacosmos Therapeutics INC. | $23.50 | 2023 | Monoferric |
| Rigel Pharmaceuticals, INC. | $21.52 | 2022 | |
| Puma Biotechnology, INC. | $19.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.56 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.97 | 2020 | |
| Pfizer INC. | $16.74 | 2021 | |
| G1 Therapeutics, INC. | $15.68 | 2022 | |
| Servier Pharmaceuticals LLC | $15.60 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $15.18 | 2020 | |
| Adc Therapeutics America, INC. | $12.47 | 2021 | |
| Morphosys, US INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.